Key Highlights

• Ansell reported its FY26 result on 24 August 2026.

• Sales were a record US$2,140.2 million, up 6.8 per cent, with organic constant-currency growth of 5.0 per cent.

• Adjusted EBIT rose 14.1 per cent to US$321.9 million, and adjusted net profit after tax rose 15.8 per cent to US$212.3 million.

• Adjusted Earnings Per Share were 148.6 US cents, up 17.8 per cent.

How does a glove and protection company grow profit faster than sales while absorbing tariffs and Supply disruption? For Ansell Limited (ASX:ANN), the FY26 result points to a mix of pricing, sourcing changes and cost savings, with management guiding to higher earnings per share again in FY27.

The central development: FY26 results and FY27 guidance

Ansell reported its FY26 result on 24 August 2026. All figures below are in US dollars. Sales were a record US$2,140.2 million, up 6.8 per cent, with organic constant-currency growth of 5.0 per cent. Adjusted EBIT rose 14.1 per cent to US$321.9 million, and adjusted net profit after tax rose 15.8 per cent to US$212.3 million. Adjusted earnings per share were 148.6 US cents, up 17.8 per cent.

For FY27, the company guided to adjusted earnings per share of 158 to 170 US cents, and said it expects constant-currency sales growth from more encouraging volumes and recent pricing actions. This matters because earnings growth is running ahead of sales growth, which suggests Operating Leverage and cost control are contributing alongside demand.

What Ansell does and how it earns

Ansell makes hand and body protection products. Its Industrial Business supplies gloves and protective equipment for manufacturing, construction, chemical handling and similar workplaces. Its Healthcare business supplies surgical and examination gloves and related products for hospitals, clinics and cleanrooms.

Revenue is driven by volumes, product mix and pricing. Innovation in higher-value products, such as mechanical protection gloves, supports price and margin, while commodity-style products are more exposed to competition and input costs.

Operating performance

Both segments reported higher sales and earnings. Industrial was helped by mechanical glove innovation and recovery in major markets. Healthcare was supported by Demand for cleanroom and surgical products.

Cash generation was a standout. Operating Cash Flow was US$270.1 million, up 156.3 per cent. Cash flow can swing sharply with working capital, so a large percentage increase should be read with that in mind, but the company said cash generation supports its capital management plans.

The full-year Dividend was 68.1 US cents per share, up 35.7 per cent, including a final dividend of 41.5 US cents. The company also continued an on-market share buy-back, part of a US$200 million program, with US$118.4 million completed in FY26. The reports reviewed gave the buy-back figure as "$" without a currency code, so it is assumed to be in US dollars. Buy-backs are planned to continue in FY27.

Balance sheet and cost programs

Ansell reported US$752 million of cash and undrawn facilities, and net Debt of 1.3 times adjusted EBITDA. A cost program known as the Accelerated Productivity Investment Program reached its target of US$50 million in recurring annual savings.

US tariffs and Middle East supply disruptions were offset through sourcing changes and price rises, according to the company. That is a useful point, because it shows management has been able to pass through some cost increases, although the benefit of price rises can fade if competitors respond or demand softens.

Reading the growth rates

Several of the headline growth rates differ, and the gaps are informative. Reported sales rose 6.8 per cent while organic constant-currency growth was 5.0 per cent, so part of the increase came from factors other than underlying Volume and price, such as currency effects. The summaries reviewed do not itemise this, so the results release is the place to check. Neither gap changes the central takeaway that profit grew faster than sales.

That gap is consistent with a lower share count after buy-backs, though it is an interpretation rather than a company statement.

Leadership

Chief executive Nathalie Ahlström, who is in her first months in the role, described FY26 as a successful year. A new chief executive often brings a change in emphasis, so investors will be watching whether the priorities outlined for FY27 are delivered. Those priorities are profitable growth in key markets, commercial and operational excellence, productivity gains through information technology, continued buy-backs and higher dividends supported by cash generation.

Sector conditions and competitive position

Protective equipment demand is linked to industrial activity, workplace safety regulation and healthcare procedure volumes. Both parts of the business can be steady in normal conditions, but they are not immune to cycles. Industrial customers can reduce purchasing when Manufacturing slows, and healthcare demand depends on hospital activity and stocking patterns.

Competition in gloves is intense, particularly in lower-priced categories where manufacturers in Asia compete heavily on cost. Ansell's strategy leans on branded, higher-specification products, where customers value performance and compliance as well as price.

Tariffs and shipping disruption have been important recent influences. Because Ansell sources and sells across many countries, changes in trade policy can affect cost, pricing and customer behaviour, and the effect can differ between product lines.

Material risks and upcoming developments

Management has said it will adjust for Tariff and geopolitical risks as conditions change. The main uncertainties include trade policy and tariffs, raw material and freight costs, foreign exchange movements, competition in commodity-style products and the possibility that price rises slow volumes.

Guidance is not a guarantee, and outcomes can differ from it. The FY27 range of 158 to 170 US cents is wide enough to leave room for both a modest and a more encouraging outcome, and it depends on assumptions about demand and costs.

Upcoming developments include progress on the buy-back, any trading commentary at the annual general meeting, and the half-year result in early 2027, the date of which should be confirmed on the company's investor calendar.